SK
Skye Bioscience, Inc.
SKYE · NASDAQ
$1.71 -6.04% (-$0.11)
1M -21.20%
Market Cap $7.51M
P/E Ratio -
Div. Yield -
ROE 329.08%
Bulios Fair Price
$1.95
14.0% upside
Current Price
$1.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SKYE is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
40 /100
Average ROA 457.62%
ROIC 11,243.10%
Asset turnover 0.00x
Debt
15 /100
High Int. coverage -9,182.19x
Current ratio 0.95x
Debt/Assets N/A
Stability
1 /100
Unstable Profitable years 0
Beta 2.90x
EPS volatility 93.02%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SKYE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Punit Dhillon
Employees
2
Headquarters
San Diego
Upcoming events
09 NOV
Earnings
Upcoming earnings report